Venlo, the Netherlands, Oct. 30, 2023 QIAGEN announced results for the third quarter and first nine months of 2023. Net sales results of $470 million at constant exchange rates for Q3 2023.
Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Net sales at CER of $470 million ahead of outlook for at least $465 million CER and adjusted diluted EPS of $0.50 CER ahead of outlook for at least $0.48 CER // 5% CER sales growth in non-COVID portfolio to $442 million, supported by higher sales from instruments as well as recurring consumables and related revenues // 9M 2023: 8% CER sales grow
QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0 50 CER tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Venlo, the Netherlands, Oct. 04, 2023 QIAGEN today announced the launch of its QuantiFERON-EBV RUO assay. Epstein-Barr virus , or human herpes virus 4, is estimated in various epidemiological.